Johnson & Johnson Total Assets Growth & History (JNJ)
Johnson & Johnson's total assets was $199.21B for fiscal 2025.
View full Johnson & Johnson company overviewJohnson & Johnson annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-28 | $199.21B | $19.11B | +10.61% |
| 2024 | 2024-12-29 | $180.10B | $12.55B | +7.49% |
| 2023 | 2023-12-31 | $167.56B | −$19.82B | −10.58% |
| 2022 | 2023-01-01 | $187.38B | $5.36B | +2.94% |
| 2021 | 2022-01-02 | $182.02B | $7.12B | +4.07% |
| 2020 | 2021-01-04 | $174.89B | $17.17B | +10.88% |
| 2019 | 2019-12-29 | $157.73B | $4.77B | +3.12% |
| 2018 | 2018-12-30 | $152.95B | −$4.35B | −2.76% |
| 2017 | 2017-12-31 | $157.30B | $16.09B | +11.40% |
| 2016 | 2017-01-01 | $141.21B | $7.80B | +5.84% |
| 2015 | 2016-01-03 | $133.41B | $3.05B | +2.34% |
| 2014 | 2014-12-28 | $130.36B | −$2.33B | −1.75% |
| 2013 | 2013-12-29 | $132.68B | $11.34B | +9.34% |
| 2012 | 2012-12-30 | $121.35B | $7.70B | +6.78% |
| 2011 | 2012-01-01 | $113.64B | $10.74B | +10.43% |
| 2010 | 2011-01-02 | $102.91B | $8.23B | +8.69% |
| 2009 | 2010-01-03 | $94.68B | $9.77B | +11.51% |
| 2008 | 2008-12-28 | $84.91B | — | — |
Johnson & Johnson quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-28 | $201.06B | $7.67B | +3.97% |
| Q1 2026 | 2026-03-29 | $200.89B | $7.22B | +3.73% |
| Q4 2025 | 2025-12-28 | $199.21B | $19.11B | +10.61% |
| Q3 2025 | 2025-09-28 | $192.82B | $14.53B | +8.15% |
| Q2 2025 | 2025-06-29 | $193.39B | $12.30B | +6.79% |
| Q1 2025 | 2025-03-30 | $193.67B | $21.70B | +12.62% |
| Q4 2024 | 2024-12-29 | $180.10B | $12.55B | +7.49% |
| Q3 2024 | 2024-09-29 | $178.29B | $12.23B | +7.36% |
| Q2 2024 | 2024-06-30 | $181.09B | −$10.60B | −5.53% |
| Q1 2024 | 2024-03-31 | $171.97B | −$24.00B | −12.25% |
| Q4 2023 | 2023-12-31 | $167.56B | −$19.82B | −10.58% |
| Q3 2023 | 2023-10-01 | $166.06B | −$9.06B | −5.18% |
| Q2 2023 | 2023-07-02 | $191.69B | $13.96B | +7.86% |
| Q1 2023 | 2023-04-02 | $195.97B | $17.61B | +9.88% |
| Q4 2022 | 2023-01-01 | $187.38B | $5.36B | +2.94% |
| Q3 2022 | 2022-10-02 | $175.12B | −$4.10B | −2.29% |
| Q2 2022 | 2022-07-03 | $177.72B | $1.28B | +0.73% |
| Q1 2022 | 2022-04-03 | $178.35B | $5.80B | +3.36% |
| Q4 2021 | 2022-01-02 | $182.02B | — | — |
| Q3 2021 | 2021-10-03 | $179.23B | $8.54B | +5.00% |
| Q2 2021 | 2021-07-04 | $176.44B | $18.06B | +11.40% |
| Q1 2021 | 2021-04-04 | $172.56B | $17.54B | +11.31% |
| Q4 2020 | 2021-01-04 | $174.89B | $17.17B | +10.88% |
| As of Jan 3, 2021 | 2021-01-03 | $174.89B | $17.17B | +10.88% |
| Q3 2020 | 2020-09-27 | $170.69B | $15.17B | +9.76% |
| Q2 2020 | 2020-06-28 | $158.38B | $3.26B | +2.10% |
| Q1 2020 | 2020-03-29 | $155.02B | $4.99B | +3.33% |
| Q4 2019 | 2019-12-29 | $157.73B | $4.77B | +3.12% |
| Q3 2019 | 2019-09-29 | $155.52B | −$182.0M | −0.12% |
| Q2 2019 | 2019-06-30 | $155.12B | −$248.0M | −0.16% |
| Q1 2019 | 2019-03-31 | $150.03B | −$6.60B | −4.21% |
| Q4 2018 | 2018-12-30 | $152.95B | −$4.35B | −2.76% |
| Q3 2018 | 2018-09-30 | $155.70B | $45.0M | +0.03% |
| Q2 2018 | 2018-07-01 | $155.37B | $2.56B | +1.67% |
| Q1 2018 | 2018-04-01 | $156.63B | $11.71B | +8.08% |
| Q4 2017 | 2017-12-31 | $157.30B | $16.09B | +11.40% |
| Q3 2017 | 2017-10-01 | $155.66B | $15.29B | +10.89% |
| Q2 2017 | 2017-07-02 | $152.81B | $12.99B | +9.29% |
| Q1 2017 | 2017-04-02 | $144.92B | $8.69B | +6.38% |
| Q4 2016 | 2017-01-01 | $141.21B | $7.80B | +5.84% |
| Q3 2016 | 2016-10-02 | $140.37B | $7.10B | +5.33% |
| Q2 2016 | 2016-07-03 | $139.81B | $7.78B | +5.89% |
| Q1 2016 | 2016-04-03 | $136.23B | $7.64B | +5.94% |
| Q4 2015 | 2016-01-03 | $133.41B | $3.05B | +2.34% |
| Q3 2015 | 2015-09-27 | $133.27B | $1.17B | +0.88% |
| Q2 2015 | 2015-06-28 | $132.04B | −$3.16B | −2.34% |
| Q1 2015 | 2015-03-29 | $128.59B | −$4.74B | −3.56% |
| Q4 2014 | 2014-12-28 | $130.36B | −$2.33B | −1.75% |
| Q3 2014 | 2014-09-28 | $132.10B | $5.16B | +4.07% |
| Q2 2014 | 2014-06-29 | $135.20B | $10.88B | +8.75% |
| Q1 2014 | 2014-03-30 | $133.33B | $11.79B | +9.70% |
| Q4 2013 | 2013-12-29 | $132.68B | $11.34B | +9.34% |
| Q3 2013 | 2013-09-29 | $126.93B | $7.98B | +6.71% |
| Q2 2013 | 2013-06-30 | $124.33B | $8.57B | +7.41% |
| Q1 2013 | 2013-03-31 | $121.54B | $5.34B | +4.60% |
| Q4 2012 | 2012-12-30 | $121.35B | $7.70B | +6.78% |
| Q3 2012 | 2012-09-30 | $118.95B | $7.13B | +6.38% |
| Q2 2012 | 2012-07-01 | $115.75B | $3.64B | +3.24% |
| Q1 2012 | 2012-04-01 | $116.19B | $8.04B | +7.44% |
| Q4 2011 | 2012-01-01 | $113.64B | $10.74B | +10.43% |
| Q3 2011 | 2011-10-02 | $111.82B | $13.57B | +13.82% |
| Q2 2011 | 2011-07-03 | $112.11B | $19.81B | +21.47% |
| Q1 2011 | 2011-04-03 | $108.15B | $14.71B | +15.74% |
| Q4 2010 | 2011-01-02 | $102.91B | $8.23B | +8.69% |
| Q3 2010 | 2010-10-03 | $98.25B | $6.69B | +7.31% |
| Q2 2010 | 2010-07-04 | $92.30B | $4.86B | +5.56% |
| Q1 2010 | 2010-04-04 | $93.44B | — | — |
| Q4 2009 | 2010-01-03 | $94.68B | $9.77B | +11.51% |
| Q3 2009 | 2009-09-27 | $91.56B | — | — |
| Q2 2009 | 2009-06-28 | $87.44B | — | — |
| Q4 2008 | 2008-12-28 | $84.91B | — | — |
Johnson & Johnson total assets trends
Over the last five fiscal years, Johnson & Johnson's total assets increased from $174.89B to $199.21B, a change of $24.32B. The latest reported quarter, Q2 2026, shows $201.06B.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Johnson & Johnson source filings ↗Community posts
Apollo reportedly nears $20 billion talks for J&J orthopedics business
Apollo ($APO) is in talks to acquire Johnson & Johnson’s ($JNJ) DePuy Synthes orthopedics business in a transaction that could be worth around $20 billion, Reuters reported, citing Bloomberg. The unit generated approximately $9.3 billion in ...